Enter Note Done
Go to previous page in this tab
Event
  • Scientific Session
  • Bookmark Icon
  • Advancing Medical Device Safety with Human-Relevant New Approach Methodologies
  • Schedule
    Notes
  • Hemisfair Ballroom C3‚ Convention Center
    Set Timezone


Chair: Kelly Coleman, Medtronic
Co-Chair: Ron Brown, Risk Science Consortium

Primary Endorser: Medical Device and Combination Product Specialty Section


Endorser(s): In Vitro and Alternative Methods Specialty Section


Medical device safety assessment is undergoing a transformation as human-relevant methods increasingly replace animal-based approaches. While animal models have historically been the default tools for evaluating device safety, they often provide limited human relevance and mechanistic insight, particularly for endpoints driven by localized tissue responses or immune activation. Advances in human-relevant New Approach Methodologies (NAMs) now offer scientifically robust alternatives that can improve biological relevance, enhance interpretability, and support efficient regulatory decision-making. This scientific informational session will examine how NAMs are being applied in medical device safety assessment today, highlighting both established successes and ongoing challenges to broader implementation. The session will first explore in vitro skin irritation testing using reconstructed human epidermis (RhE) models, which represent one of the most mature and widely adopted NAMs for medical devices. International validation and standard-setting activities have demonstrated that RhE assays can reliably assess skin irritation potential of medical device extracts within defined contexts of use. Multi-laboratory studies have shown strong accuracy for distinguishing irritant from non-irritant materials, high within- and between-laboratory reproducibility, and good concordance with historical intracutaneous rabbit tests and available human data. The session will discuss how these data underpin ISO 10993-23, where RhE-based methods are identified as the preferred approach for skin irritation evaluation, and how clear performance criteria and acceptance thresholds have enabled these assays to function as stand-alone replacements for animal testing in routine biological evaluation strategies. Attention will then shift to pyrogenicity, a critical safety endpoint linked to innate immune activation and systemic inflammatory responses. Traditional reliance on the Rabbit Pyrogen Test has increasingly been challenged by the availability of human-relevant in vitro methods. Specifically, the session will examine the Monocyte Activation Test (MAT), which uses human immune cells to quantify cytokine release in response to pyrogens, enabling detection of both endotoxin and non-endotoxin pyrogens. New experimental data and a critical review of the literature will be integrated to evaluate MAT performance for medical device surface testing and to examine the biological plausibility of so-called 'material-mediated pyrogens' described in existing standards. Findings indicate that the MAT provides robust, quantitative detection of true microbial pyrogens, while offering little support for the hypothesis that chemically pure materials can elicit pyrogenic responses in the absence of biological contamination. Sample preparation, output interpretation, and lessons-learned will be shared. Next, in vitro skin sensitization testing for medical devices will be addressed, focusing on how sensitization assays and integrated approaches can be applied to complex device materials and extracts. Discussion will center on interpretation of assay outputs, use of weight-of-evidence frameworks, and alignment of sensitization NAM data with regulatory expectations in medical device submissions. Finally, the session will place these case studies within the broader context of NAM implementation and regulatory uptake. Topics will include fit-for-purpose validation strategies, defined approaches to interpret results, integrated testing and assessment frameworks, and the role of sustained engagement among method developers, regulators, and stakeholders. Federal initiatives and international harmonization efforts aimed at accelerating the adoption of human-relevant NAMs will be discussed, along with remaining barriers and practical pathways forward. Overall, this session will provide Society of Toxicology attendees with real-world examples of how human-relevant NAMs are improving medical device safety assessment, while offering a roadmap for expanding their scientifically defensible use across multiple toxicological endpoints.

Session and Activity Type
Presentations